79,265 XNAS Volume
XNAS 24 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Michael J. LaCascia | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 126,000 | 126,000 | - | - | Stock Option (right to buy) | |
| Adrian Gottschalk | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Steven F. Bellon | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
| Kristian F. Humer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| Carlos Costa | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 115,000 | 115,000 | - | - | Stock Option (right to buy) | |
| Anna Rivkin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Carlos Costa | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 20 Sep 2024 | 35,756 | 35,756 | - | 3.7 | 133,012 | Common Stock |
| Carlos Costa | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 857 | 39,789 | - | - | Stock Option (right to buy) | |
| Carlos Costa | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 35,756 | 40,646 | - | - | Stock Option (right to buy) | |
| Carlos Costa | Chief People Officer | Sale of securities on an exchange or to another person at price $ 10.17 per share. | 20 Sep 2024 | 857 | 0 | - | 10.2 | 8,716 | Common Stock |
| Carlos Costa | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 20 Sep 2024 | 857 | 857 | - | 3.7 | 3,188 | Common Stock |
| Carlos Costa | Chief People Officer | Sale of securities on an exchange or to another person at price $ 10.04 per share. | 20 Sep 2024 | 35,756 | 0 | - | 10.0 | 358,990 | Common Stock |
| Carlos Costa | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 18 Sep 2024 | 11,574 | 11,574 | - | 3.7 | 43,055 | Common Stock |
| Carlos Costa | Chief People Officer | Sale of securities on an exchange or to another person at price $ 10.05 per share. | 18 Sep 2024 | 11,574 | 0 | - | 10.1 | 116,319 | Common Stock |
| Carlos Costa | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2024 | 11,574 | 76,402 | - | - | Stock Option (right to buy) | |
| Carlos Costa | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 10,272 | 87,976 | - | - | Stock Option (right to buy) | |
| Carlos Costa | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 400 | 98,248 | - | - | Stock Option (right to buy) | |
| Carlos Costa | Chief People Officer | Sale of securities on an exchange or to another person at price $ 10.04 per share. | 16 Sep 2024 | 10,272 | 0 | - | 10.0 | 103,131 | Common Stock |
| Carlos Costa | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 16 Sep 2024 | 10,272 | 10,272 | - | 3.7 | 38,212 | Common Stock |
| Carlos Costa | Chief People Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 16 Sep 2024 | 400 | 0 | - | 10 | 4,000 | Common Stock |
| Carlos Costa | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 16 Sep 2024 | 400 | 400 | - | 3.7 | 1,488 | Common Stock |
| Steven F. Bellon | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.50 per share. | 09 Sep 2024 | 20,000 | 101,957 | - | 9.5 | 190,000 | Common Stock |
| Anna Rivkin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 190,000 | 190,000 | - | - | Stock Options (Right to buy) | |
| B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 16,000 | 16,000 | - | - | Stock Options (Right to buy) | |
| Ian F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 16,000 | 16,000 | - | - | Stock Options (Right to buy) | |
| Thomas J. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 16,000 | 16,000 | - | - | Stock Options (Right to buy) | |
| Adam M. Koppel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 16,000 | 16,000 | - | - | Stock Options (Right to buy) | |
| Scott Biller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 16,000 | 16,000 | - | - | Stock Options (Right to buy) | |
| Kristian F. Humer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 275,000 | 275,000 | - | - | Stock Option (Right to buy) | |
| Fanny Cavalie | Chief Strategy/Bus Ops Officer | Sale of securities on an exchange or to another person at price $ 6.56 per share. | 11 Mar 2024 | 11,000 | 75,992 | - | 6.6 | 72,134 | Common Stock |
| F. Bellon Steven | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| LaCascia Michael J. | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Costa Carlos | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Fanny Cavalie | Chief Strategy/Bus Ops Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Adrian Gottschalk | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Smith Ian F. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 26,977 | 26,977 | - | - | Stock Option (right to buy) | |
| Adrian Gottschalk | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Aug 2023 | 63,000 | 511,704 | - | 0 | Common Stock | |
| Adrian Gottschalk | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Aug 2023 | 63,000 | 0 | - | 0 | Common Stock | |
| Samuel Agresta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 311,297 | 0 | - | - | Stock Option (right to buy) | |
| Samuel Agresta | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.25 per share. | 16 Aug 2023 | 311,297 | 0 | - | 8.2 | 2,568,200 | Common Stock |
| Samuel Agresta | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 16 Aug 2023 | 311,297 | 311,297 | - | 3.7 | 1,158,025 | Common Stock |
| B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Ian F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Thomas J. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Adam M. Koppel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Scott Biller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Adrian Gottschalk | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 26 May 2023 | 300,000 | 448,704 | - | 0 | Common Stock | |
| Adrian Gottschalk | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 26 May 2023 | 300,000 | 448,704 | - | 0 | Common Stock | |
| Michael J. LaCascia | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Samuel Agresta | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Adrian Gottschalk | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 280,000 | 280,000 | - | - | Stock Option (right to buy) | |
| Steven F. Bellon | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Fanny Cavalie | Chief Strategy/Bus Ops Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Carlos Costa | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Thomas J. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 32,000 | 32,000 | - | - | Stock Options (Right to buy) | |
| Adrian Gottschalk | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 16 Sep 2022 | 40,000 | 186,479 | - | 0.5 | 21,600 | Common Stock |
| Adrian Gottschalk | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2022 | 40,000 | 418,925 | - | - | Stock Option (right to buy) | |
| B. Lynne Parshall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 32,000 | 32,000 | - | - | Stock Options (Right to buy) | |
| Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 1,858 | 3,716 | - | - | Stock Options (Right to buy) | |
| Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 11 Aug 2022 | 1,858 | 121,957 | - | 3.7 | 6,912 | Common Stock |
| Carlos Costa | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Ian F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 16,000 | 16,000 | - | - | Stock Options (Right to buy) | |
| Adam M. Koppel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 16,000 | 16,000 | - | - | Stock Options (Right to buy) | |
| Scott Biller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 16,000 | 16,000 | - | - | Stock Options (Right to buy) | |
| Cigall Kadoch | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 16,000 | 16,000 | - | - | Stock Options (Right to buy) | |
| Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 675 | 0 | - | - | Stock Options (Right to buy) | |
| Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 3,717 | 5,574 | - | - | Stock Options (Right to buy) | |
| Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 25 May 2022 | 3,717 | 120,099 | - | 3.7 | 13,827 | Common Stock |
| Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.73 per share. | 25 May 2022 | 675 | 116,382 | - | 0.7 | 493 | Common Stock |
| Adrian Gottschalk | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Feb 2022 | 184,939 | 448,704 | - | 0 | Common Stock | |
| Adrian Gottschalk | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Feb 2022 | 123,479 | 23,000 | - | 0 | Common Stock | |
| Adrian Gottschalk | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Feb 2022 | 123,479 | 448,704 | - | 0 | Common Stock | |
| Adrian Gottschalk | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Feb 2022 | 4,371 | 67,371 | - | 0 | Common Stock | |
| Adrian Gottschalk | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Feb 2022 | 4,371 | 444,333 | - | 0 | Common Stock | |
| Adrian Gottschalk | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Feb 2022 | 4,371 | 63,000 | - | 0 | Common Stock | |
| Adrian Gottschalk | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Feb 2022 | 4,371 | 448,704 | - | 0 | Common Stock | |
| Adrian Gottschalk | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 10 Feb 2022 | 184,939 | 448,704 | - | 0 | Common Stock | |
| Michael J. LaCascia | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (right to buy) | |
| Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (right to buy) | |
| Samuel Agresta | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Adrian Gottschalk | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 440,000 | 440,000 | - | - | Stock Option (right to buy) | |
| Steven F. Bellon | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Cigall Kadoch | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Dec 2021 | 333,333 | 295,000 | - | 0 | Common Stock | |
| Carl P. Decicco | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 09 Dec 2021 | 104,310 | 362,707 | - | 3.7 | 388,033 | Common Stock |
| Carl P. Decicco | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2021 | 76,892 | 186,571 | - | - | Stock Options (Right to buy) | |
| Carl P. Decicco | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2021 | 27,418 | 34,273 | - | - | Stock Options (Right to buy) | |
| Adrian Gottschalk | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 23,000 | 458,925 | - | - | Stock Options (Right to buy) | |
| Adrian Gottschalk | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 20 Aug 2021 | 23,000 | 446,479 | - | 0.5 | 12,420 | Common Stock |
| Allan Reine | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 09 Aug 2021 | 26,892 | 53,784 | - | 3.7 | 100,038 | Common Stock |
| Allan Reine | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 26,892 | 257,512 | - | - | Stock Options (Right to buy) | |
| Adam M. Koppel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2021 | 12,530 | 12,530 | - | - | Stock Option (right to buy) | |
| Scott Biller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2021 | 12,530 | 12,530 | - | - | Stock Option (right to buy) | |
| Cigall Kadoch | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2021 | 12,530 | 12,530 | - | - | Stock Option (right to buy) | |
| Ian F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 12,530 | 12,530 | - | - | Stock Options (Right to buy) | |
| Ian F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 25,060 | 25,060 | - | - | Stock Options (Right to buy) | |
| Allan Reine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Samuel Agresta | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Adrian Gottschalk | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Carl P. Decicco | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Adrian Gottschalk | Director, See Remarks | 27 Oct 2020 | 25,225 | 25,225 | - | - | Common Stock | ||
| Adrian Gottschalk | Director, See Remarks | 27 Oct 2020 | 18,018 | 0 | - | - | Series A-2 Convertible Preferred Stock | ||
| Adrian Gottschalk | Director, See Remarks | 27 Oct 2020 | 7,207 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Carl P. Decicco | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 27 Oct 2020 | 5,500 | 258,397 | - | 16 | 88,000 | Common Stock |